Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.

Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.

Item
http://www.wikidata.org/entity/Q33392822
Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.Polymeric nanocarriers for the treatment of systemic iron overload.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Deferasirox: pharmacokinetics and clinical experience.Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.Deferasirox nephrotoxicity-the knowns and unknowns.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.Safety profiles of iron chelators in young patients with haemoglobinopathies.Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures
P2860

Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.

Item
http://www.wikidata.org/entity/Q33392822
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@ast
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
type
label
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@ast
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
prefLabel
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@ast
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1537-2995.2010.02939.X
P433
P478
P577
P698
P921